BACKGROUND: Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals. PBL has a poor prognosis, but prognostic factors in patients who have received chemotherapy have not been adequately evaluated. METHODS: An extensive literature search rendered 248 cases of PBL, from which 157 were HIV(+). Seventy cases with HIV-associated PBL that received chemotherapy were identified. Whenever possible, authors of the original reports were contacted to complete clinicopathological data. Univariate analyses were performed calculating Kaplan-Meier estimates and compared using the log-rank test. RESULTS: The mean age was 39 years, with a male predominance. The mean CD4(+) count was 165 cells/mm(3). Advanced clinical stage was seen in 51% and extraoral involvement was seen in 43% of the cases. The expression levels of CD20 and Epstein-Barr virus-encoded RNA were 13% and 86%, respectively. The overall survival duration was 14 months. In a univariate analysis, early clinical stage and a complete response to chemotherapy were associated with longer survival. There was no apparent difference in survival with regimens more intensive than cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). CONCLUSIONS: Patients with HIV-associated PBL have a poor prognosis. Prognosis is strongly associated with achieving a complete clinical response to CHOP or CHOP-like chemotherapy. The role of more intensive regimens is currently unclear. Further research is needed to improve responses using novel therapeutic agents and strategies.
BACKGROUND:Plasmablastic lymphoma (PBL) is a variant of diffuse large B-cell lymphoma commonly seen in the oral cavity of HIV-infected individuals. PBL has a poor prognosis, but prognostic factors in patients who have received chemotherapy have not been adequately evaluated. METHODS: An extensive literature search rendered 248 cases of PBL, from which 157 were HIV(+). Seventy cases with HIV-associated PBL that received chemotherapy were identified. Whenever possible, authors of the original reports were contacted to complete clinicopathological data. Univariate analyses were performed calculating Kaplan-Meier estimates and compared using the log-rank test. RESULTS: The mean age was 39 years, with a male predominance. The mean CD4(+) count was 165 cells/mm(3). Advanced clinical stage was seen in 51% and extraoral involvement was seen in 43% of the cases. The expression levels of CD20 and Epstein-Barr virus-encoded RNA were 13% and 86%, respectively. The overall survival duration was 14 months. In a univariate analysis, early clinical stage and a complete response to chemotherapy were associated with longer survival. There was no apparent difference in survival with regimens more intensive than cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). CONCLUSIONS:Patients with HIV-associated PBL have a poor prognosis. Prognosis is strongly associated with achieving a complete clinical response to CHOP or CHOP-like chemotherapy. The role of more intensive regimens is currently unclear. Further research is needed to improve responses using novel therapeutic agents and strategies.
Authors: Patrick Adam; Tiemo Katzenberger; Harald Seeberger; Stefan Gattenlöhner; Juergen Wolf; Claus Steinlein; Michael Schmid; Hans-Konrad Müller-Hermelink; German Ott Journal: Am J Surg Pathol Date: 2003-11 Impact factor: 6.394
Authors: Richard Lester; Charles Li; Peter Phillips; Tamara N Shenkier; Randy D Gascoyne; Paul F Galbraith; Linda M Vickars; Heather A Leitch Journal: Leuk Lymphoma Date: 2004-09
Authors: H J Delecluse; I Anagnostopoulos; F Dallenbach; M Hummel; T Marafioti; U Schneider; D Huhn; A Schmidt-Westhausen; P A Reichart; U Gross; H Stein Journal: Blood Date: 1997-02-15 Impact factor: 22.113
Authors: Lawrence D Kaplan; Jeannette Y Lee; Richard F Ambinder; Joseph A Sparano; Ethel Cesarman; Amy Chadburn; Alexandra M Levine; David T Scadden Journal: Blood Date: 2005-05-24 Impact factor: 22.113
Authors: Mark Bower; Brian Gazzard; Sundhiya Mandalia; Tom Newsom-Davis; Christina Thirlwell; Tony Dhillon; Anne Marie Young; Tom Powles; Andrew Gaya; Mark Nelson; Justin Stebbing Journal: Ann Intern Med Date: 2005-08-16 Impact factor: 25.391
Authors: Ariela Noy; Shelly Y Lensing; Page C Moore; Neel Gupta; David Aboulafia; Richard Ambinder; Robert Baiocchi; Bruce J Dezube; David Henry; Lawrence Kaplan; Alexandra M Levine; Ronald Mitsuyasu; Lee Ratner; Erin Reid; Scot Remick; Joseph Sparano; Dimitrios Tzachanis; William Wachsman; Amy Chadburn Journal: Leuk Lymphoma Date: 2015-12-16